Cara Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher A. Posner
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4 Stamford Plaza Stamford CT United States of America 06902
- IPO Date
- Jan 31, 2014
- CIK
- 0001346830
- Website
- caratherapeutics.com
- Similar Companies
- Business
- Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities that selectively target kappa opioid receptors, primarily addressing pruritus and pain management. Its flagship product, KORSUVA (difelikefalin) injection, is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company also has product candidates in clinical trials targeting pruritus related to atopic dermatitis, non-dialysis-dependent chronic kidney disease, chronic liver disease, and notalgia paresthetica. Founded in 2006 and headquartered in Stamford, Connecticut, Cara operates mainly in the United States with development pipelines focused on novel therapeutic approaches for chronic pruritus and pain. In terms of recent major changes, Cara Therapeutics announced a 1-for-3 reverse stock split in April 2025 in connection with its upcoming merger with Houston-based Tvardi Therapeutics, a clinical-stage biopharmaceutical company specializing in treatments targeting STAT3 for fibrosis-driven diseases. This merger is expected to create a Nasdaq-listed combined entity with Cara shareholders owning approximately 17% of the new company. Additionally, Cara has entered into an asset purchase agreement to sell certain rights to the development, manufacture, and commercialization of difelikefalin (KORSUVA) to Vifor Fresenius Medical Care Renal Pharma Ltd. for $900,000, with additional compensation for future expenses. The company discontinued the development of oral difelikefalin for notalgia paresthetica due to lack of meaningful clinical benefit found in a Phase 2/3 study, pivoting instead towards strategic alternatives to maximize shareholder value. These changes mark a significant strategic shift towards focusing on late-stage development programs and leveraging partnerships to sustain operations and growth. Cara Therapeutics’ product portfolio is centered on kappa opioid receptor agonists with KORSUVA aimed at pruritus in chronic kidney disease patients on hemodialysis and ongoing clinical candidates targeting pain and other pruritus indications. The company's proprietary technology targets peripheral kappa opioid receptors to minimize central nervous system side effects. The company’s business segments include biopharmaceutical development and commercialization in nephrology and dermatology markets. Cara’s strategic merger and asset sales underline a transition toward broadening its therapeutic focus while optimizing its financial and operational structure in the competitive biotech landscape.
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
GRAMMY-WINNING ARTIST ALESSIA CARA PARTNERS WITH LENOVO AND INTEL FOR THE "MADE BY" CAMPAIGN, FEATURING A BEHIND-THE-SCENES MINISERIES AND EXCLUSIVE LIVE EXPERIENCE
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Why Is Cara Therapeutics (CARA) Stock Down 27% Today?
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript